Assessing Short-term Treatment Satisfaction and Quality of Life in Patients With Hidradenitis Suppurativa Initiated on Secukinumab in Routine Clinical Practice in the United Arab Emirates: ILLUMINATE-HS, a Prospective Patient Surve
Latest Information Update: 24 Jun 2026
At a glance
- Drugs Secukinumab (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Acronyms ILLUMINATE-HS
- Sponsors Novartis Pharmaceuticals
Most Recent Events
- 16 Jun 2026 Planned End Date changed from 30 Sep 2026 to 10 Oct 2026.
- 16 Jun 2026 Planned primary completion date changed from 30 Sep 2026 to 10 Oct 2026.
- 01 Apr 2026 Status changed from recruiting to active, no longer recruiting.